|Bid||50.00 x 100|
|Ask||65.00 x 200|
|Day's Range||57.29 - 58.10|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.38|
Seattle Genetics Inc. has appointed Alpna Seth to its board of directors, expanding the board to nine people including two women. Seth’s more than 20 years of experience in health care and biotechnology will help Seattle Genetics continue to build out its growing pipeline of cancer drugs, which includes four applications of its flagship drug Adcetris. “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company,” Seth said in a news release.
Seattle Genetics, Inc. announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen.
Seattle Genetics, Inc. announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time.
Seattle Genetics, Inc. today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced program in Cascadian Therapeutics’ pipeline is tucatinib, an investigational oral tyrosine kinase inhibitor that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric....
Seattle Genetics, Inc. today announced the expiration of the tender offer by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics, Inc. today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma .
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m.
Seattle Genetics, Inc. today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc.
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
MADRID , Feb. 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics ...
Stock Monitor: Seattle Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Pieris Pharmaceuticals, Inc. (NASDAQ: ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc.
Seattle Genetics, Inc. today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Array BioPharma has been on fire all week after announcing encouraging data results and strong earnings for its second quarter. Shares of Seattle Genetics ...
The Bothell, Washington-based company said it had a loss of 41 cents per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
Seattle Genetics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, enfortumab vedotin and tisotumab vedotin clinical activities, as well as progress with its pipeline of targeted therapies for cancer.